← Leaderboards
Parvathi Ranganathan
Ohio State University
$1,925,208
Attributed
$4,752,648
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,752,648 · 2
By mechanism
R01$4,752,648 · 2
Top collaborators
- Hannah Choe5 shared
- Adrienne M. Dorrance4 shared
- Ramiro Garzon4 shared
Most similar at Ohio State University
Same institution · by research overlap
- Janice K Kiecolt-Glaser$29,757,164
- Mauro Ferrari$18,839,277
- Hannah Choe$1,022,976
- Swagata Goswami$644,678
- Yang Liu$21,443,530
Others in their field
Other Emerging Leaders on “Refractory”
- John Damon Chodera · Sloan-Kettering Inst Can Research$13,706,419
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Christopher B. Granger · Duke University$9,106,303
- Crystal Mackall · Children'S Hosp Of Philadelphia$8,791,590
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$6,328,779
- Patricio Sepulveda · Amplo Biotechnology, Inc.$5,506,739
Research focus
RefractoryProteinsNovel TherapeuticsMouse ModelComplicationPreventDendritic CellsHematological DiseaseImmune ReconstitutionInterferon Type IiCell PhysiologyBiologyPhenotypePreclinical StudyAcute Graft Versus Host DiseaseCytokineGraft Vs Leukemia EffectFutureAffectHomologous TransplantationInflammationInflammatoryAllogenicResponse
Grant awards (9)
Developing novel therapies to improve blood stem cell transplantation outcomes$630,428
R01 · FY2025 · HL
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD$415,000
R01 · FY2025 · CA
Developing novel therapies to improve blood stem cell transplantation outcomes$620,713
R01 · FY2024 · HL
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD$394,251
R01 · FY2024 · CA
Developing novel therapies to improve blood stem cell transplantation outcomes$671,563
R01 · FY2023 · HL
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD$406,701
R01 · FY2023 · CA
Developing novel therapies to improve blood stem cell transplantation outcomes$783,992
R01 · FY2022 · HL
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD$415,000
R01 · FY2022 · CA
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD$415,000
R01 · FY2021 · CA